Taylor Heath
Primary Care · Sparta, MONPI 1518602259
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$627
- Lilly USA, LLC$511
- AbbVie$454
- Otsuka America Pharmaceutical, Inc.$362
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$183
- Merck$165
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,369100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $627 |
| Lilly USA, LLC | 35 | $511 |
| AbbVie | 35 | $454 |
| Otsuka America Pharmaceutical, Inc. | 20 | $362 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $183 |
| Merck | 10 | $165 |
| Novo Nordisk | 27 | $156 |
| Corium, LLC | 11 | $152 |
| Teva Pharmaceuticals USA, Inc. | 6 | $108 |
| Lundbeck LLC | 6 | $108 |
| Axsome Therapeutics, Inc. | 6 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Boehringer Ingelheim | 4 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Exact Sciences | 2 | $32 |
| Edwards Lifesciences | 2 | $31 |
| Pfizer | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $16 |
| Novartis | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,369 in reported general payments places this provider in the 90th percentile of 106 primary care providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 11 | $80,891 |
| RexultiBrexpiprazole | 35 | $51,951 |
| FarxigaDapagliflozin Propanediol | 33 | $22,342 |
| OzempicSemaglutide | 23 | $21,897 |
| EliquisApixaban | 24 | $14,610 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,980 |
| JanuviaSitagliptin Phosphate | 15 | $12,965 |
| LinzessLinaclotide | 14 | $11,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,269 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,936 |
| Varenicline Tartrate | 32 | $7,555 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,302 |
| MovantikNaloxegol Oxalate | 12 | $5,107 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $4,814 |
| Nicardipine Hcl | 14 | $2,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $362 | $51,95135 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $627 | $36,32255 claims |
| Novo NordiskOzempic | $156 | $21,89723 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $20 | $18,20532 claims |
| PfizerEliquis | $31 | $14,61024 claims |
| MerckJanuvia | $165 | $12,96515 claims |
| AbbVieLinzess | $454 | $11,70214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $70 | $7,30215 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $108 | $54412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 primary care providers in Missouri.
Other primary care in Sparta
- Katrina SelsorSparta$6K
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
- Melanie HenryHayti$4K
- Heather BealSaint Louis$4K
- Ashley TitchenalSaint Louis$3K
- Avonne RosarioKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.